R&D 5 changes underway for R&D IT shifting to advanced modalitie... Back in 2000, the FDA approved only six biologics versus 27 new molecular entities (NMEs).
News Astellas pays $285m for Audax cancer drug, and other deals Astellas takes an option on a cancer immunotherapy developed by Audax for up to $1.34bn, with Gilead and Teva also adding to their pipelines.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
